Side-by-side comparison of AI visibility scores, market position, and capabilities
$2.56B revenue 2024; Q2 2025 $631.9M (-1.6% YoY); 101-103M projected US members 2025; telehealth market leader; telehealth market $123.26B 2024 to $455.27B 2030; 46.58% North America share
Teladoc Health is the world's largest telehealth company, founded in 2002 and headquartered in Purchase, New York, that pioneered on-demand virtual healthcare delivery in the United States. The company was founded on the premise that patients should be able to access physicians anytime and anywhere without traveling to a physical office — a model that took over a decade to gain mainstream acceptance before becoming a necessity during the COVID-19 pandemic. Teladoc's mission is to provide whole-person virtual care that addresses physical health, mental health, and chronic condition management through an integrated digital platform.\n\nTeladoc's platform encompasses general medical, dermatology, nutrition, and specialty care through its core telehealth offering; mental health and therapy through BetterHelp, the world's largest online therapy platform; virtual primary care and chronic condition management through Teladoc Primary360; and complex care navigation through its integrated whole-person health approach. The company serves employers, health plans, hospitals, and health systems, delivering virtual care to members across the US and internationally. BetterHelp has become a significant consumer-facing revenue driver, connecting individuals directly with licensed therapists without employer or insurance intermediaries.\n\nTeladoc reported $2.56 billion in revenue for 2024 and projects 101 to 103 million US members in 2025. The company trades on the NYSE under TDOC and holds a substantial lead in telehealth market share through its scale, multi-specialty breadth, and direct-to-consumer mental health reach via BetterHelp. Despite post-pandemic normalization and the $13.7 billion Livongo write-down in 2022, Teladoc remains the largest and most diversified virtual care platform, with continued investment in AI-powered clinical decision support and chronic disease management to drive the next phase of growth.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Teladoc Health vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.